The use of Nucleo C.M.P. Forte in the comprehensive treatment of diabetic polyneuropathy
Keywords:diabetes mellitus, diabetic polyneuropathy, Nucleo C.M.P. Forte
AbstractBackground. Diabetes mellitus (DM) is one of the socially significant diseases. At the time of manifestation of DM, up to 6 % of patients have signs of diabetic polyneuropathy (DPN), after 5 years of the disease, they are observed in 15 %, and after 15 years — in 25 % of patients with DM. About 80 % of patients with DPN are asymptomatic, and the painful form of DPN is diagnosed in 10–20 % of cases. Sometimes, DPN precedes the onset of clinical signs of DM. For adequate treatment of DPN, it is necessary to know that pathogenesis of neuropathy in DM is associated with overall metabolic lesion of neuronal membranes. The objective was to study the effectiveness of Nucleo C.M.P. Forte in the comprehensive treatment of DPN. Materials and methods. Thirty patients with DM types 1 and 2 (8 men and 22 women) and DPN were examined. The level of glycated hemoglobin was from 7.1 to 10.4 %. The first group (15 patients) received: alpha-lipoic acid at a dose of 600 mg intravenously, B vitamins: injections — for 10 days while in hospital and tablets — for one month at home. The second group (15 patients) before treatment received by group 1 was treated with Nucleo C.M.P. Forte intramuscularly for 10 days while in hospital, then 1 capsule twice a day for 2 months. In all patients before administration of the drug, after 10 days of in-hospital treatment and 2 months after treatment, clinical neurological examination was performed to evaluate neurological status, as well as dynamic examination using special clinical questionnaires (scales): Neurological Symptom Score and Total Symptom Score. Results. Patients in both the first group and the second groups had a statistically positive effect on the symptoms after 10 days of in-patient treatment according to Neurological Symptom Score. The severity of neuropathy in first group before treatment was 10.23 ± 0.35 points, and after treatment — 7.62 ± 0.26 points, p < 0.001; in the second group, before treatment — 10.23 ± 0.35 points, and after treatment — 8.00 ± 0.30 points, p < 0.001. According to Total Symptom Score, the severity of neuropathy symptoms decreased significantly in both group 1 (8.27 ± 0.47 points before treatment and 6.27 ± 0.12 points after treatment, p < 0.001) and group 2 (8.40 ± 0.45 points before treatment and 6.53 ± 0.14 points after treatment, p < 0.001). Further studies showed that after 2 months of treatment in patients in first group, Neurological Symptom Score (10.23 ± 0.35 points, p > 0.05) and Total Symptom Score (7.87 ± 0.38 points, p > 0.05) returned to the baseline or the changes were unreliable. Two-month administration of Nucleo C.M.P. Forte had a statistically positive effect on the symptoms of neuropathy according to Neurological Symptom Score (7.27 ± 0.51 points, p < 0.001) and Total Symptom Score (6.53 ± 0.14 points, p < 0.001). Conclusions. The use of Nucleo C.M.P. Forte in the comprehensive treatment of patients with diabetes mellitus can prevent disorders that occur as a result of diabetic polyneuropathy. Long-term statistically significant positive effect of Nucleo C.M.P. Forte on neuropathy symptoms was revealed.
Moghtaderi A, Bakhshipour A, Rashidi H. Validation of Michigan neuropathy screening instrument for diabetic peripheral neuropathy. Clin Neurol Neurosurg. 2006 Jul;108(5):477-81. doi: 10.1016/j.clineuro.2005.08.003.
Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A; KORA Study Group. Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3. Pain Med. 2009 Mar;10(2):393-400. doi: 10.1111/j.1526-4637.2008.00555.x.
Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010 Oct;33(10):2285-93. doi: 10.2337/dc10-1303.
Sadosky A, Mardekian J, Parsons B, Hopps M, Bienen EJ, Markman J. Healthcare utilization and costs in diabetes relative to the clinical spectrum of painful diabetic peripheral neuropathy. J Diabetes Complications. 2015 Mar;29(2):212-7. doi: 10.1016/j.jdiacomp.2014.10.013.
Van Acker K, Bouhassira D, De Bacquer D, et al. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab. 2009 Jun;35(3):206-13. doi: 10.1016/j.diabet.2008.11.004.
Alleman CJ, Westerhout KY, Hensen M, et al. Humanistic and economic burden of painful diabetic peripheral neuropathy in Europe: a review of the literature. Diabetes Res Clin Pract. 2015 Aug;109(2):215-25. doi: 10.1016/j.diabres.2015.04.031.
Binns-Hall O, Selvarajah D, Sanger D, Walker J, Scott A, Tesfaye S. One-stop microvascular screening service: an effective model for the early detection of diabetic peripheral neuropathy and the high-risk foot. Diabet Med. 2018 Jul;35(7):887-894. doi: 10.1111/dme.13630.
Vlasenko MV. Quality of Life in Patients with Diabetes Mellitus Type 2 with Metabolic Neuropathy against Pathogenic Therapy. Mìžnarodnij endokrinologìčnij žurnal. 2013;(49). doi: 10.22141/2224-07188.8.131.523.84052.
How to Cite
Copyright (c) 2019 M.V. Vlasenko, A.V. Palamarchuk, S.V. Shkarivska
This work is licensed under a Creative Commons Attribution 4.0 International License.